Up-and-coming Chinese pharmaceutical companies are turning to AI to speed up drug discovery, aiming to cut costs and fast-track promising treatments from the lab to the market. One standout, Nanjing-based Genscript Biotech, is leveraging its own AI tools—like enzyme prediction databases and gene-editing algorithms—to pinpoint and refine potential drug candidates more efficiently.

Editor’s Note: This isn’t just about keeping up with global rivals—it’s a sign of how AI is reshaping drug development everywhere. Faster, cheaper discoveries could mean quicker access to life-saving treatments, and China’s push into this space could shake up the industry. For patients, that’s a win. For Big Pharma, it’s a nudge to innovate faster.